Latest News for FLNA
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug. 1
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for FLNA.
Senate Trading
No Senate trades found for FLNA.
U.S. House Trading
No House trades found for FLNA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.